Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination.
Pool V, Gordon DM, Decker M.
Arch Neurol. 2012 Jan;69(1):144; author reply 144-5. No abstract available.
Related citations
Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution.
Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA.
Arch Neurol. 2012 Jan;69(1):129-32.
Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis.
Caramanos Z, Francis SJ, Narayanan S, Lapierre Y, Arnold DL.
Arch Neurol. 2012 Jan;69(1):89-95.
Impact of inflammation on brain volume in multiple sclerosis.
Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D.
Arch Neurol. 2012 Jan;69(1):82-8.
Daclizumab use in patients with pediatric multiple sclerosis.
Gorman MP, Tillema JM, Ciliax AM, Guttmann CR, Chitnis T.
Arch Neurol. 2012 Jan;69(1):78-81.
Magnetic resonance techniques in multiple sclerosis: the present and the future.
Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G.
Arch Neurol. 2011 Dec;68(12):1514-20. Review.
No endovascular innovation without evaluation in chronic cerebrospinal venous insufficiency: a call for the IDEAL model.
Williams MA, Venkatesan A.
Arch Neurol. 2011 Dec;68(12):1510-2. No abstract available.
Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, Brieva L, Téllez N, Perkal H, Comabella M, Galán I, Calle D, Sastre-Garriga J, Rovira A.
Arch Neurol. 2011 Nov;68(11):1421-7.
Brain involvement in neuromyelitis optica spectrum disorders.
Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW.
Arch Neurol. 2011 Nov;68(11):1432-9.
Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, Cadeddu RP, Weigelt C, Fischer U, Kobbe G, Hartung HP, Adams O, Kieseier BC, Haas R.
Arch Neurol. 2011 Nov;68(11):1428-31.
Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ.
Arch Neurol. 2011 Nov;68(11):1412-20. Epub 2011 Jul 11.
Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.
Arch Neurol. 2012 Feb;69(2):183-90. Epub 2011 Oct 10.
Lack of response to monoclonal antibody therapy in neuromyelitis optica.
Qian P, Cross AH, Naismith RT.
Arch Neurol. 2011 Sep;68(9):1207-9. No abstract available.
No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis.
Marder E, Gupta P, Greenberg BM, Frohman EM, Awad AM, Bagert B, Stüve O.
Arch Neurol. 2011 Dec;68(12):1521-5. Epub 2011 Aug 8.
Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?
Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, Brenner T, Argov Z, Karussis D.
Arch Neurol. 2011 Dec;68(12):1557-61. Epub 2011 Aug 8.
Use of mitoxantrone in neuromyelitis optica.
Kitley JL, Leite MI, Matthews LA, Palace J.
Arch Neurol. 2011 Aug;68(8):1086; author reply 1086-7. No abstract available.
Chronic cerebrospinal venous insufficiency and multiple sclerosis.
Bagert BA, Marder E, Stüve O.
Arch Neurol. 2011 Nov;68(11):1379-84. Epub 2011 Jul 11. Review.
How safe could intrathecal transplantation of mesenchymal stem cells be considered in multiple sclerosis?
Karacostas D, Hadjigeorgiou G, Ioannidis P, Milonas I.
Arch Neurol. 2011 Jul;68(7):955; authors reply 955-6. No abstract available. Erratum in: Arch Neurol. 2011 Sep;68(9):1164.
A benign form of neuromyelitis optica: does it exist?
Collongues N, Cabre P, Marignier R, Zéphir H, Papeix C, Audoin B, Lebrun-Frenay C, Pelletier J, Fontaine B, Vermersch P, Confavreux C, de Seze J; Group Members for NOMADMUS and CF-SEP.
Arch Neurol. 2011 Jul;68(7):918-24.
Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica.
Uzawa A, Mori M, Masuda S, Kuwabara S.
Arch Neurol. 2011 Jul;68(7):913-7.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on